Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,701,051.96 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of Roivant Sciences stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now owns 1,127,290 shares in the company, valued at $12,197,277.80. This trade represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $10.44 on Thursday. Roivant Sciences Ltd. has a 52-week low of $9.96 and a 52-week high of $13.06. The business’s fifty day moving average is $10.77 and its 200 day moving average is $11.43. The firm has a market cap of $7.45 billion, a price-to-earnings ratio of -69.60 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $17.10.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at about $39,000. GAMMA Investing LLC boosted its position in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Quarry LP increased its position in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.